Madrigal Pharmaceuticals (STU:YDO1) Total Assets : €995.70 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Madrigal Pharmaceuticals Total Assets?

Madrigal Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 was €995.70 Mil.

During the past 12 months, Madrigal Pharmaceuticals's average Total Assets Growth Rate was 681.20% per year. During the past 3 years, the average Total Assets Growth Rate was 31.10% per year. During the past 5 years, the average Total Assets Growth Rate was 23.40% per year. During the past 10 years, the average Total Assets Growth Rate was 19.50% per year.

During the past 13 years, Madrigal Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 208.90%. The lowest was -71.20%. And the median was 6.40%.

Total Assets is connected with ROA %. Madrigal Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2024 was -68.59%. Total Assets is also linked to Revenue through Asset Turnover. Madrigal Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Madrigal Pharmaceuticals Total Assets Historical Data

The historical data trend for Madrigal Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Madrigal Pharmaceuticals Total Assets Chart

Madrigal Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

397.85

235.91

241.90

342.27

587.38

Madrigal Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial															310.51	279.17	222.97	587.38	995.70

Madrigal Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Madrigal Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	371.69	+	215.691
	=	587.38

Madrigal Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	782.698	+	212.999
	=	995.70

Madrigal Pharmaceuticals (STU:YDO1) Total Assets Explanation

Total Assets is connected with ROA %.

Madrigal Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-542.952	/	( (587.382	+	995.698)	/ 2 )
	=	-542.952	/	791.54
	=	-68.59 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Madrigal Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	0	/	( (587.382	+	995.698)	/ 2 )
=	0	/	791.54
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Madrigal Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of Madrigal Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Madrigal Pharmaceuticals (STU:YDO1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Madrigal Pharmaceuticals Inc (STU:YDO1) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

MDGL:USA YDO1:Germany

Address

200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428

Website

http://www.madrigalpharma.com

Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Madrigal Pharmaceuticals (STU:YDO1) Headlines

No Headlines